<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02497118</url>
  </required_header>
  <id_info>
    <org_study_id>TMUCIH-ENDU-S001</org_study_id>
    <nct_id>NCT02497118</nct_id>
  </id_info>
  <brief_title>Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC</brief_title>
  <official_title>Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study mainly to observe the anti angiogenic drugs Endostatin (Endostar) combined with
      vinorelbine and Cisplatin (NP) as neoadjuvant therapy in patients with non small cell lung
      cancer clinical efficiency and safety. Through anti angiogenesis therapy combined with
      neoadjuvant chemotherapy improve the treatment of neoadjuvant therapy in tumor response rate
      and the rate of resection, At the same time, the study before and after the anti angiogenesis
      therapy in patients with peripheral blood circulation endothelial cells(CECs), levels of
      Endothelial progenitor cells（EPC）, micro vascular density（MVD） and vascular endothelial
      growth factor(VEGF) expression level, to understanding the correlation between the clinical
      efficacy of anti angiogenesis therapy combined with chemotherapy and the change of all these
      markers. In order to find the reference basis for the prediction of the effect of curative
      effect. The changes of blood volume, blood flow and vascular permeability of the lung cancer
      before and after treatment with CT perfusion imaging are studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Regression Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Target lesion size reduction ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival is defined as the time from randomization to disease recurrence or death which comes first.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>the time from randomization to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Endostatin plus NP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug:Endostatins Intravenous drip， 7.5mg/m^2, d1-14 drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NP neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostatin</intervention_name>
    <description>Endostatin,7.5mg/m^2,intravenous, d1-14;</description>
    <arm_group_label>Endostatin plus NP</arm_group_label>
    <other_name>Endostar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>vinorelbine,25mg/m^2,intravenous, d1, d8;</description>
    <arm_group_label>Endostatin plus NP</arm_group_label>
    <arm_group_label>NP neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin，75mg/m^2 intravenous,divide into d1-3</description>
    <arm_group_label>Endostatin plus NP</arm_group_label>
    <arm_group_label>NP neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The pathology proved to be non small cell lung cancer (must be histologically).

          -  At present, the patients with ⅢA stage (N2) were evaluated by the assistant
             examination;

          -  The patients were evaluated by imaging, laboratory examination and other examination;

          -  Without chemotherapy or anti angiogenic therapy;

          -  There can be measured lesions

          -  Informed consent.

        Exclusion Criteria:

          -  Pregnant, lactating women, or patients with fertility but did not take contraceptive
             measures.

          -  Severe infection.

          -  Severe heart disease.Neuropsychiatric disorders, which is not easy to control.

          -  Severe diabetes.

          -  There is obvious bleeding tendency.

          -  The 5 years history of other tumors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2015</study_first_submitted>
  <study_first_submitted_qc>July 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2015</study_first_posted>
  <last_update_submitted>July 13, 2015</last_update_submitted>
  <last_update_submitted_qc>July 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer Anti angiogenesis therapy survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

